Ximedica is owned by SV Life Sciences and Paul LaViolette is the chairman of the Ximedica and Transenterix boards. My best guess is he bought Ximedica for either one of two reasons:
1) to get control of Titan/SPORT;
2) to put them out of business and get the IP dirt cheap.
Titan is being squeezed on multiple fronts (financing & development) and by multiple sources (Chinese, Ximedica, investors).
The share price reflects as much (most I believe know that the share price would be rising IF there was great potential negotiations going on behind the scenes). Also, remember Fowler was an insider up until a few weeks ago and would have never left IF negotiations were happening behind the scenes IMHO.
Everybody should think long and hard about these things.
What happens if investors aren't willing to finance a shelf offering any longer and be continually diluted because of the way Rayman/Hargove have treated them over the years? NO PR/IR communications and continually moving the goal posts. If they only have 3-6 months of cash left, what happens when they run out. Many in the business will WANT this to happen. Many competitors.
If the share price of Titan were to drop to $.05 in the next few months and eventually Titan gets an offer of $.10, management will say to shareholders, look how we were able to NEGOTIATE a 100% premium of share price for you. Take it, because we have no more money and will go BK if you don't.
If Titan can't pay Ximedica what it owes them, can Ximedica force liquidation?
Food for thought and possible bad case scenarios I know, but these things could happen. We are in the darkest period with Titan right now and I must admit, my critique of the strategy and execution that Rayman/Fowler have adopted has been relatively accurate. There has been very little that has been able to move the share price.
News 
Market Data 
Discover 
AI
